Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma

Inclusion Criteria:

• Relapsed or refractory multiple myeloma who received at least one prior therapyincluding thalidomide, bortezomib, or lenalidomide-containing regimen

• Subjects with measurable disease defined as at least one of the following SerumM-protein ≥ 1.0 g/dL Urine M-protein ≥ 400 mg/24hr

• Eastern Cooperative Oncology Group Performance Status ≤ 2

• Hemoglobin ≥ 8 g/dL (≥ 4.96 mol/L): Prior red blood cell transfusion or recombinanthuman erythropoietin use is allowed.

• Absolute neutrophil count (ANC) ≥ 1.0 x 109/L

• Aspartate aminotransferase (AST) < 3 times the upper limit of normal

• Alanine aminotransferase (ALT) < 3 times the upper limit of normal

• Subjects (or their legally acceptable representatives) must have signed an informedconsent document indicating that they understand the purpose of and proceduresrequired for the study and are willing to participate in the study

Exclusion Criteria:

• Smoldering or indolent myeloma

• Uncontrolled or severe cardiovascular disease (cardiac ejection fraction<0.5, Severeconduction disorder )

• Sepsis or current active infection

• Pregnancy or breastfeeding

• Received other immunotherapy treatment

• Clinically significant autoimmune disease

• Serious medical or psychiatric illness likely to interfere with participation in thisclinical study